Chinese market

Chinese market


Chinese market

Depression is a common global disease. According to data released by the World Health Organization, as of 2022, 350 million people worldwide suffer from depression, and 5% of adults worldwide suffer from depression every year. Family relationships, life pressures, peer interactions, and other factors have woven a complex web, trapping many people in the pain of depression.

Depression includes severe depression, recurrent depression, psychotic depression, postpartum depression, and seasonal depression. But while depression is showing a trend towards younger age, the rate of seeking medical treatment has always been low. On the one hand, when facing depression, people may not realize that it is a disease, and not only ignore the related symptoms and patients, but also discriminate against them. On the other hand, depression is prone to misdiagnosis and missed diagnosis.

Since the COVID-19, more than 70 million depression patients, 90 million anxiety patients and hundreds of millions of people have insomnia problems worldwide. A recent report issued by the World Health Organization also shows that in the first year of the COVID-19 pandemic, the global incidence rate of anxiety and depression has increased by 28%.

The definition of 'health' by the World Health Organization is not just the absence of illness or physical weakness, but always emphasizes a person's mental integrity and good social adaptation. In a state of mental health, individuals are able to recognize their abilities, cope with normal stress in daily life, work effectively, and contribute to their society. More specifically, a person with mental health is interested in his own work, can self-acceptance, can adjust his emotions, adapt well to the environment and have good interpersonal relationships.

But in fact, there are over 400 known psychological disorders, with the most common being depression, anxiety disorders, and various sleep disorders. "The incidence rate of depressive disorder in China is about 7%, and more than 10% in European and American countries." Lu Lin said, "The incidence rate of anxiety disorder is about 7%, and it reaches 15% in many countries." In addition, 20% to 30% of adults have all kinds of sleep problems

As the most common psychological disorders, depression and anxiety can currently receive better treatment. Among them, 70% to 80% of patients can be effectively treated, and some patients can recover. However, only about 20% of depression patients receive timely treatment, and most people do not recognize this as a disease or avoid problems.

Xinluoding ® (venlafaxine Hydrochloride Sustained Release Tablets) The fifth batch of products selected for centralized drug procurement organized by the state!

Xinluoding ® (venlafaxine Hydrochloride Sustained Release Tablets) belong to 5-hydroxytryptamine and norepinephrine reuptake inhibitors. It can act on the two receptor systems of 5-hydroxytryptamine and norepinephrine, which is commonly referred to as the dual channel drug in clinical practice. Compared with the single channel drug, it has more receptors and stronger efficacy.

Xinluoding ® (venlafaxine Hydrochloride Sustained Release Tablets) is: the Supplementary Drug Application Approval for venlafaxine Hydrochloride Sustained Release Tablets (trade name: Xinleding) issued by the State Food and Drug Administration (approval number: 2021B02331). The venlafaxine Hydrochloride Sustained Release Tablets declared by our company passed the evaluation of the consistency of the quality and efficacy of the generic drugs, and was the first osmotic pump technology over evaluated product in Anhui. Priority use of clinically replaceable original research drugs!

Xinluoding ® (venlafaxine Hydrochloride Sustained Release Tablets) is safe and effective in the treatment of depression and anxiety patient safety:

· Quickly acting, with a better cure rate than SSRIs

· Overall good safety

· Venlafaxine sustained-release agent that passed the consistency evaluation and won the bid for the fifth round of centralized procurement of the country, is a safe choice for clinical use

· The unique sustained-release dosage form is the first line drug for depression and anxiety recommended by domestic and international guidelines for Class A and base drugs of medical insurance




Investment promotion service information:

Hefei Huafang Pharmaceutical Technology Co., Ltd.


Add:Building D-5, Science and Technology Industrial Park, No. 168 Xiangzhang Avenue, National High tech Zone, Hefei

Investment hotline:0551-65312033;13956059199(same WeChat account)


Contact person: Ye Hua

Scan the QR code to read on your phone

Huafang Pharmceutical Sciences



Add: Building D-5, Technology Industrial Park, 168 Xiangzhang Avenue, National High-tech Zone, Hefei City





Copyright © Huafang Pharmceutical